Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Ojemda on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Ojemda (tovorafenib) is a kinase inhibitor approved by the FDA under accelerated approval for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation.
Ojemda is a type II RAF kinase inhibitor that blocks abnormal BRAF-driven signaling in tumor cells, helping to slow or shrink glioma growth in patients whose tumors carry these specific genetic alterations.
Ojemda is intended for pediatric and young patients with low-grade glioma that has relapsed or is refractory to prior treatment, and whose tumor has been confirmed to carry a BRAF fusion, rearrangement, or V600 mutation through appropriate testing.
Ojemda dosing is based on body surface area, at 380 mg/m² (maximum 600 mg per week) taken orally once weekly, available as tablets or an oral suspension for patients unable to swallow tablets.
Ojemda does not carry a formal FDA boxed warning. However, patients and caregivers should be aware of the following important safety information.
Cases of hemorrhage have been reported. Patients should be monitored for signs of bleeding during treatment.
Ojemda can cause skin reactions and increased sensitivity to sunlight. Patients should use sun protection and avoid prolonged sun exposure during treatment.
Liver enzyme elevations have been observed. Liver function should be monitored periodically during treatment.
Because Ojemda is used in pediatric patients, growth should be monitored routinely, as effects on growth and bone development are possible with prolonged treatment.
Ojemda may cause fetal harm. Effective non-hormonal contraception is recommended during treatment for patients of reproductive potential.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Ojemda is manufactured and marketed by Day One Biopharmaceuticals. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating pediatric oncologist confirming diagnosis, BRAF alteration testing results, and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for relapsed or refractory pediatric low-grade glioma, Ojemda is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Ojemda directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Ojemda should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Ojemda through NPP's regulated import pathway, with pediatric oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support pediatric oncology care coordination and documentation for Ojemda access.
Delhi's major hospitals assist patients with prescription support and documentation for Ojemda.
Bangalore's specialist network offers access coordination for eligible pediatric glioma patients seeking Ojemda.
Chennai-based pediatric oncology specialists coordinate Ojemda access alongside comprehensive glioma care.
Hyderabad's care institutions support patients pursuing Ojemda therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Ojemda.
Pune-based specialists assist with prescription support and Ojemda treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Ojemda.
Kochi's specialist units assist patients with the documentation needed for Ojemda access.
Chandigarh's care centers support Ojemda treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Ojemda access process.
Lucknow-based centers assist patients pursuing Ojemda therapy.
Bhubaneswar's institutions support access to Ojemda for eligible patients.
Guwahati's specialists help coordinate Ojemda access for patients across the Northeast.
Patients in other cities across India can also access Ojemda through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.webp)
